FDAnews
www.fdanews.com/articles/72890-glycogenesys-gets-gcs-100-patent-to-treat-angiogenesis-related-diseases

GlycoGenesys Gets GCS-100 Patent to Treat Angiogenesis-Related Diseases

June 1, 2005

The U.S. Patent and Trademark Office has issued a patent protecting the use of GlycoGenesys' drug candidate GCS-100 and other modified pectins to control angiogenesis (the process by which new blood vessels are formed) and to treat angiogenesis-dependent diseases.

Angiogenesis plays an important role in cancer where GCS-100 is currently being tested, as well as, macular degeneration, endometriosis and many other diseases which rely on the formation of new vasculature.